Category: Top Story
-
Investors Exit Large Caps, Turn to Small Caps After Fed Rate Cut, Says BofA
Bank of America Securities reported that investors shifted their focus last week, pulling money out of large-cap stocks and redirecting funds toward small caps in the wake of the Federal Reserve’s rate cut. It was the biggest withdrawal from large caps in over two years, while small caps recorded inflows in three of the last…
-
Tesla Q3 Deliveries Could Surpass Wall Street Estimates, UBS Predicts
Tesla (NASDAQ:TSLA) may report third-quarter deliveries that exceed Wall Street expectations, UBS analysts say. In a note to clients, the bank raised its forecast to roughly 475,000 vehicles, describing it as “~8% above Visible Alpha consensus,” while noting it is “more inline with buyside expectations in the 470–475k range.” This represents an upward revision from…
-
Stronger U.S. fiscal position could drive long-term Treasury yields lower, Barclays says
Barclays analysts argue that the U.S. fiscal outlook has “materially improved,” helped by higher tariff revenues and the beginning of the Federal Reserve’s easing cycle—factors that could support a decline in long-dated Treasury yields. In a research note, the bank said concerns over the bond market sparked by President Donald Trump’s flagship budget bill earlier…
-
AI boom and wealthy spending may not sustain U.S. economic growth, Warns BCA
Spending by affluent American households and the surge in technology investment in artificial intelligence might not be sufficient to keep the U.S. economy out of recession, according to BCA Research analysts. In a research note, strategists led by Doug Peta said that even though they raised their stock outlook earlier this month due to the…
-
Top 5 Oncology Stocks to Watch: Barclays
Barclays has identified several standout opportunities in the Oncology and Inflammation & Immunology (I&I) space, spotlighting companies advancing innovative protein degradation platforms and targeted therapies. These stocks are seen as attractive based on upcoming catalysts, clinical results, and current market valuations. 1. Kymera Therapeutics (NASDAQ:KYMR)Barclays initiated coverage of KYMR with an Overweight rating and a…
-
U.S. consumer prices rose in August in line with expectations
The Commerce Department reported Friday that consumer prices in the U.S. increased in August, matching economist forecasts. The personal consumption expenditures (PCE) price index advanced 0.3% last month, following a 0.2% increase in July, aligning with market expectations. The annual growth rate of the PCE price index edged up to 2.7% in August from 2.6%…
-
Dow Jones, S&P, Nasdaq, Wall Street Futures, U.S. Stocks Eye Rebound as Inflation Data Meets Forecasts
U.S. stock futures signaled a potential recovery Friday after several sessions of declines, with investors showing interest in purchasing equities at lower levels. Recent dips had reflected concerns over elevated valuations and uncertainty surrounding the artificial intelligence sector. Futures gained momentum following the release of August’s consumer price data from the Commerce Department, which came…
-
PACCAR shares surge on Trump’s heavy truck tariff announcement
PACCAR Inc (NASDAQ:PCAR) saw its stock climb 6% Friday morning following U.S. President Donald Trump’s decision to impose a 25% tariff on imported heavy-duty trucks, a move expected to favor domestic producers. The new tariffs, scheduled to take effect on October 1, 2025, are part of a broader package of duties that has unsettled automotive…
-
Boeing lands major jet deals with Turkish Airlines and Norwegian Air
Boeing (NYSE:BA) announced fresh momentum on Friday after securing large aircraft orders from Turkish Airlines and Norwegian Air Shuttle, helping strengthen the U.S. planemaker’s recovery efforts. The stock was up 0.5% in premarket trading. Turkish Airlines, officially Turk Hava Yollari, confirmed a record commitment for as many as 75 787 Dreamliners, its largest purchase of…
-
Novartis downplays effect of new U.S. pharmaceutical tariff
Novartis (NYSE:NVS), the Swiss pharmaceutical leader, said on Friday that the newly introduced 100% U.S. tariff on branded drugs “should have no impact” on its business. The company emphasized that its $23 billion investment in American infrastructure, along with the rollout of new production sites across the country, helps shield operations from potential consequences of…